% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Janke:292528,
author = {F. Janke$^*$ and F. Stritzke$^*$ and K. Dvornikovich and H.
Franke and A. K. Angeles$^*$ and A. L. Riediger$^*$ and S.
Ogrodnik$^*$ and S. Gerhardt$^*$ and S. Regnery and P.
Schröter and L. Bauer and K. Weusthof and M. Görtz$^*$ and
S. Harrabi$^*$ and K. Herfarth$^*$ and C. Neelsen$^*$ and D.
Paech$^*$ and H.-P. Schlemmer$^*$ and A. Abdollahi$^*$ and
S. Adeberg$^*$ and J. Debus$^*$ and H. Sültmann$^*$ and T.
Held$^*$},
title = {{E}arly circulating tumor {DNA} changes predict outcomes in
head and neck cancer patients under re-radiotherapy.},
journal = {International journal of cancer},
volume = {156},
number = {4},
issn = {0020-7136},
address = {Bognor Regis},
publisher = {Wiley-Liss},
reportid = {DKFZ-2024-01774},
pages = {853-864},
year = {2025},
note = {#EA:B063#EA:E050#LA:B063#LA:E050# / 2025 Feb
15;156(4):853-864},
abstract = {Local recurrence after radiotherapy is common in locally
advanced head and neck cancer (HNC) patients. Re-irradiation
can improve local disease control, but disease progression
remains frequent. Hence, predictive biomarkers are needed to
adapt treatment intensity to the patient's individual risk.
We quantified circulating tumor DNA (ctDNA) in sequential
plasma samples and correlated ctDNA levels with disease
outcome. Ninety four longitudinal plasma samples from 16
locally advanced HNC patients and 57 healthy donors were
collected at re-radiotherapy baseline, after 5 and 10
radiation fractions, at irradiation end, and at routine
follow-up visits. Plasma DNA was subjected to low coverage
whole genome sequencing for copy number variation (CNV)
profiling to quantify ctDNA burden. CNV-based ctDNA burden
was detected in 8/16 patients and 25/94 plasma samples. Ten
additional ctDNA-positive samples were identified by
tracking patient-specific CNVs found in earlier sequential
plasma samples. ctDNA-positivity after 5 and 10 radiation
fractions (both: log-rank, p = .050) as well as at the end
of irradiation correlated with short progression-free
survival (log-rank, p = .006). Moreover, a pronounced
decrease of ctDNA toward re-radiotherapy termination was
associated with worse treatment outcome (log-rank, p =
.005). Dynamic ctDNA tracking in serial plasma beyond
re-radiotherapy reflected treatment response and imminent
disease progression. In five patients, molecular progression
was detected prior to tumor progression based on clinical
imaging. Our findings emphasize that quantifying ctDNA
during re-radiotherapy may contribute to disease monitoring
and personalization of adjuvant treatment, follow-up
intervals, and dose prescription.},
keywords = {circulating tumor DNA (Other) / copy number variations
(Other) / head and neck cancer (Other) / predictive
biomarker (Other) / re‐radiotherapy (Other)},
cin = {B063 / E250 / E050 / E210 / HD01 / E010},
ddc = {610},
cid = {I:(DE-He78)B063-20160331 / I:(DE-He78)E250-20160331 /
I:(DE-He78)E050-20160331 / I:(DE-He78)E210-20160331 /
I:(DE-He78)HD01-20160331 / I:(DE-He78)E010-20160331},
pnm = {315 - Bildgebung und Radioonkologie (POF4-315)},
pid = {G:(DE-HGF)POF4-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:39212345},
doi = {10.1002/ijc.35152},
url = {https://inrepo02.dkfz.de/record/292528},
}